Saturday 17 October 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.19 | — | — | — |
P/S ratio |
0.06 | — | — | — | |
P/FCF ratio |
0.14 | — | — | — | |
P/Operating CF |
(16.18) | — | — | — | |
P/B ratio |
0.05 | — | — | — | |
Price to Tangible BV |
0.05 | — | — | — | |
EV/Sales |
(1.02) | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(1.83) | — | — | — | |
EV/FCF |
(2.17) | — | — | — | |
Quick Ratio |
9.73 | 11.22 | 2.05 | 5.95 | |
Current Ratio |
9.89 | 11.39 | 2.07 | 6.07 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
1.55% | 2.40% | 3.74% | 4.68% | |
Debt/Equity |
0.02 | 0.03 | 0.07 | 0.06 | |
Asset Turnover |
0.76 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(2.86) | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (0.84) | (0.55) | (0.44) | |
Interest Coverage |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
107.86% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
165.00% | — | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Graham Net Nets |
15.89 | — | — | — | |
Graham Number |
307.63 | — | — | — | |
Earnings Yield |
531.22% | — | — | — | |
Free Cash Flow Yield |
727.69% | — | — | — | |
Revenue per Share |
1.40 | — | — | — | |
Operating CF per Share |
(0.40) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(92.90) | (495.90) | (337.18) | (341.49) | |
Working Capital |
10,579.40 | 10,169.83 | 5,375.38 | 5,533.25 | |
Capital Expenditures |
(92.90) | (57.01) | (26.53) | (19.72) | |
Net Current Asset Value |
10,281.28 | 9,758.34 | 4,733.20 | 4,950.53 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
3.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
946.72 | 678.36 | 645.90 | 451.66 | |
Average Payables |
889.27 | 350.29 | 462.07 | 135.11 | |
Average Inventory |
295.37 | 264.76 | 188.07 | 143.81 | |
Average Assets |
13,180.01 | 14,825.97 | 13,526.54 | 11,126.89 | |
Average Common Equity |
9,058.62 | 10,420.99 | 7,905.74 | 7,692.95 |
Columns are period end dates